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Summary All patients with carcinoma of the breast seen in this Unit since 1970 were reviewed to study the incidence, prognosis, morbidity and response to treatment of bone metastases. The biological characteristics of the primary tumour were compared in patients relapsing first in bone or liver.
Sixty-nine percent of patients dying with breast cancer had bone metastases and bone was the commonest site of first distant relapse. Bone relapse was more common in receptor positive or well differentiated (grade 1) tumours.
The median survival was 24 months in those with disease apparently confined to the skeleton compared with 3 monlhs after fiist relapse in liver.
Ten percent of patients with breast cancer developed hypercalcaemia. All had metastatic disease and 85% had widespread skeletal involvement. Fifteen percent of patients with disease confined to the skeleton developed hypercalcaemia.
The response in bone to primary endocrine therapy, and chemotherapy, was apparently less than the overall response achieved. A large proportion had apparently static disease reflecting the insensitivity of the UICC assessment criteria. The duration of survival in these patients was similar to responding patients, suggesting a tumour response may occur in the absence of discernable radiological evidence of healing.
The majority of patients with advanced breast cancer have evidence of skeletal metastases by the time of death (Galasko, 1981) . Palliation of symptoms, control of the disease and evaluation of specific therapy are important issues in these patients. Bone metastases may remain asymptomatic but pain is common and hypercalcaemia, pathological fractures and leuco-erythroblastic anaemia may occur.
Breast cancer has a variable and often long clinical course and patients with bone metastases in particular frequently have a protracted illness. Although premature death is inevitable, remissions are frequent and patients usually require palliative therapy -local radiotherapy and specific systemic treatment -for many months or years.
Evaluating response in bone metastases to systemic therapy is often difficult. Objective assessment of response by UICC criteria (Hayward et al., 1977) requires radiological evidence of healing of lytic disease. This may not be apparent for 4-6 months and is not a direct reflection of changes in the tumour load. Clinical trills using UICC criteria have usually reported lower response rates for bone than the overall response rate achieved by treatment reflecting the insensitivity of assessment methods (Coleman & Rubens, 1985 King et al. (1979) . A value >5 fmol mg-1 cytosol protein was considered positive.
Histological grading of the primary tumour using the method of Bloom and Richardson (1957) Various systemic treatments have been used during the time period of this study. These have followed a logical sequence based on the knowledge of three variables. These are: (1) the extent, pattern and aggressiveness of the initial presentation of metastatic disease; (2) the menopausal status of the patient; (3) the hormone receptor status of the tumour. Hormone treatment has been the preferred initial treatment, chemotherapy being used for patients failing to respond to, or relapsing after, endocrine therapy. Exceptions to this are patients with aggressive visceral disease and those with hormone receptor negative tumours when cytotoxic chemotherapy is the initial treatment of choice ( Figure 1 ).
Additional treatments were used for complications of bone metastases. Hypercalcaemia was initially treated by intravenous rehydration with normal saline. Patients becoming normocalcaemic or remaining only mildly hypercalcaemic commonly received oral phosphates to maintain control. Those remaining hypercalcaemic were, until recently, treated with mithramycin or calcitonin to inhibit bone resorption, but now our present preferred agent for control of hypercalcaemia is 3 amino,l,hydroxypropylidene-l,l-bisphosphonate (APD) (Coleman & Rubens, 1986) .
To treat, or to reduce the risk of pathological fracture of a long bone, internal fixation followed by radiotherapy was performed. This usually relieved pain and provided optimum conditions for callus formation and bony union. Spinal cord compression was treated by surgical decompression if the signs were rapidly progressing, but radiotherapy was preferred for slowly progressing, previously non-irradiated sites of compression. Bone marrow infiltration causing leucoerythroblastic anaemia often occurred late in the course of the disease and, when it had become resistant to hormones, treatment was by cautious low dose chemotherapy and haematological support.
Results
Incidence and prognosis of bone metastases Bone was the most common site of metastatic disease. Four hundred and eighty-five of 587 (69%) patients dying with breast cancer in the 5 year period 1979-84 had radiological evidence of skeletal metastases before death. In comparison 158 (27%) had lung metastases, and 157 (27%) liver metastases.
Bone was also the most common site of first distant relapse. In the past ten years 2240 patients have presented to this Unit with primary breast cancer. Six hundred and eighty-one (30%) have relapsed after a median follow-up of nearly 5 years. Two-hundred and forty-five relapses (36%) were classified as local, 395 (58%) as distant and 41 (6%) concurrent local and distant. One hundred and eighty-four patients relapsed first in bone (47% of all first distant relapse). Table I shows the distribution and relative frequency of first relapse.
The mean age of patients with first relapse in either bone or in liver was 57 years (range 29-79 and 29-78 years in bone and liver respectively). Thirty-one per cent with bone Figure 1 Schema for the selection of systemic treatment for advanced breast cancer. relapse and 33% with liver relapse were premenopausal. The median disease-free interval before first relapse in either bone or liver was identical at 20 months (range 0-120 for bone and 0-91 months for liver).
The median duration of survival in 498 patients with first relapse in bone was 20 months. In 253 patients with metastatic disease apparently confined to the skeleton the median duration of survival was 24 months. The median duration of survival after first relapse in liver was only 3 months. (Figure 2 ). First relapse in bone was identified in 498 patients. Two hundred and forty-five (49%) subsequently relapsed at other sites. One hundred and forty-five (29%) developed one or more of the principal complications of bone destruction; hypercalcaemia, pathological fracture or spinal cord compression. (Table II) . (21) 129 (28) 124 (41) 1 Figure 3 . Responding patients have the best prognosis with a median duration of survival which exceeds 30 months compared with 7 months in non-responders (P= <0.001). There is no significant difference in survival between responding patients and those with static disease although the trend is in favour of those showing objective response. This suggests that a tumour response may occur in the absence of discernable radiological evidence of healing.
Tumour characteristics
Mor-bidity c aused by bone metastases Hypercalcaemia is a common complication of advanced breast cancer. One hundred and one of 1049 (10%) patients dying with breast cancer in the period 1975-84 developed hypercalcaemia. All patients with hypercalcaemia had Bone is also the commonest site of first distant relapse of breast cancer (McNeil, 1984) . In this study bone was the first site of distant relapse in 47% and viscera (liver, lung, pleura) in 25%. Despite the relative frequency of bone relapse this occurred in only 8% of 2240 patients presenting to this Unit with primary breast cancer. This low incidence in an unselected population helps explain why routine bone scanning in the follow-up of early breast cancer is not cost effective (Lee, 1985) .
Age and disease free interval were similar in patients with first relapse in either bone or in liver. Relapse in liver was not more common in pre-menopausal patients despite the tendency for lower receptor values in this group (Croton et al., 1981) . Metastatic bone disease, unlike liver disease, frequently followed a protracted clinical course. The median duration of survival was 24 months in patients with disease apparently confined to the skeleton.
This study confirms that bone metastases are more common in well differentiated receptor positive tumours, while liver metastases are more frequent with receptor negative anaplastic tumours (Elston et al., 1980) . Clinical trials in the treatment of breast cancer using the UICC criteria of response have usually reported lower reponse rates for bone lesions than the overall response (Stewart et al., 1982) . Possibly this could be a true phenomenon if bone metastases are biologically different and relatively refractory to treatment, but it seems more likely that the difference is apparent rather than real because of the insensitivity of assessment methods. Indeed the association between bone metastases and receptor positive, well differentiated tumours would predict a high response rate.
This underestimation of response to both primary endocrine therapy and chemotherapy was also seen in this study. The incidence of progressive disease was similar, but the proportion of patients with non-assessable or apparently stable disease was higher in bone. Survival from the start of endocrine treatment was similar in patients with either objective response or stable disease.
We are currently evaluating alternative response criteria including radionuclide bone scanning, biochemical parameters of bone metabolism and subjective assessment. Preliminary results show that prediction of objective response within 3-4 weeks of starting treatment is possible (Coleman et al., unpublished data) .
Morbidity from bone metastases was common. Twentynine percent of patients with first relapse in bone subsequently developed one or more of the major complications of bone destruction, hypercalcaemia, pathological fracture and spinal cord compression. The prognosis of patients with hypercalcaemia was poor with a median duration of survival of 3 months but prolonged remissions up to 56 months are seen. Better prediction of impending pathological fracture and early orthopaedic intervention might reduce the frequency of this unpleasant complication. This review of a single Unit's large experience of patients with bone metastases treated by a logical sequence of treatments has presented data on various clinical and pathological aspects of metastatic bone disease. It has confirmed the clinical importance of bone metastases, the long and usually symptomatic clinical coursc, the .1 ( relationship between tumour characteristic and sites of metastatic disease, and the difficulties in assessing response to systemic therapy. New approaches to treatment and more accurate methods of assessment are needed to improve management.
